Phenotypic and genotypic characterization of Pseudomonas aeruginosa from cystic fibrosis patients.
Pseudomonas aeruginosa accounts for about one half of all pulmonary infections of cystic fibrosis (CF) patients. In this study, we analyzed 135 P. aeruginosa strains isolated from the expectorations of 55 CF adult patients attending a CF referral center over a period of five years. We assessed the genotype of the strains by pulsed-field gel electrophoresis (PFGE) and analyzed some phenotypic characteristics, such as O serotype, enzyme and mucous production, antibiotics susceptibility, and motility. PFGE allowed the typification of 97.1% of strains, revealing the presence of nine different genomic patterns. The pattern indicated as B was the most frequent, whereas patterns H and I were the most uncommon. Serotyping failed to identify 37.8% of strains and 29 out of 55 patients harbored almost one non-typable (NT) strain. During the five years of the study, we observed a progressive reduction of O6 and O10 types, but an increase of the O1 type and of NT strains. Most strains produced protease, hemolysin, and gelatinase, and were mobile. Several patients harbored the same serotype or genotype in sequential isolates, though characterized by a different susceptibility to antimicrobials. We did not observe a relationship between bacterial genotype and phenotype. This could be due to the fact that PFGE is not sensitive enough to detect subtle genotypic differences. The epidemiological importance of the genotypic characterization of bacteria-colonizing CF subjects and the surveillance measures to be adopted in CF centers are briefly discussed.
Leone
I
I
Department of Clinical and Biological Sciences, University of Torino at S. Luigi Gonzaga Hospital, Regione Gonzole 10, Orbassano (To), Italy.
Chirillo
M G
MG
Raso
T
T
Zucca
M
M
Savoia
D
D
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000378:metabolism; D015373:Bacterial Typing Techniques; D016000:Cluster Analysis; D003550:Cystic Fibrosis / Q000150:complications* / Q000382:microbiology*; D016172:DNA Fingerprinting; D004269:DNA, Bacterial / Q000235:genetics; D016521:Electrophoresis, Gel, Pulsed-Field; D004798:Enzymes / Q000378:metabolism; D005838:Genotype; D006801:Humans; D008124:Locomotion; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D017720:Molecular Epidemiology; D019081:O Antigens / Q000032:analysis; D011135:Polysaccharides, Bacterial / Q000378:metabolism; D011552:Pseudomonas Infections / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000145:classification* / Q000187:drug effects / Q000302:isolation & purification / Q000502:physiology*; D012703:Serotyping
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D004269:DNA, Bacterial; D004798:Enzymes; D019081:O Antigens; D011135:Polysaccharides, Bacterial